Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis
- PMID: 28521680
- DOI: 10.2174/0929867324666170518101334
Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis
Abstract
Background: Fatty liver, or steatosis, is a condition of excess accumulation of lipids, mainly under form of triglycerides (TG), in the liver, and it is the hallmark of non-alcoholic fatty liver disease (NAFLD). NAFLD is the most common liver disorder world-wide and it has frequently been associated with obesity, hyperlipidemia and insulin resistance. Free fatty acids (FA) are the major mediators of hepatic steatosis; patients with NAFLD have elevated levels of circulating FA that correlate with disease severity.
Methods: Steatosis is a reversible condition that can be resolved with changed behaviors, or that can progress towards more severe liver damages such as steatohepatitis (NASH), fibrosis and cirrhosis. In NAFLD, FA of exogenous or endogenous origin accumulate in the hepatocytes and trigger liver damages. Excess TG are stored in cytosolic lipid droplets (LDs) that are dynamic organelles acting as hubs for lipid metabolism.
Results: In the first part of this review, we briefly reassumed the main classes of FA and their chemical classification as a function of the presence and number of double bonds, their metabolic pathways and effects on human health. Then, we summarized the main genetic and diet-induced animal models of NAFLD, as well as the cellular models of NAFLD.
Conclusions: In recent years, both the diet-induced animal models of NAFLD as well as the cellular models of NAFLD have found ever more application to investigate the mechanisms involved in NAFLD, and we referred to their advantages and disadvantages.
Keywords: Fatty acids; Lipid Droplets (LDs); Nonalcoholic Fatty Liver Disease (NAFLD); Reactive Oxygen Species (ROS); fatty acid oxidation; hepatic steatosis; lipid metabolism; oxidative stress..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD.Mol Metab. 2021 Aug;50:101115. doi: 10.1016/j.molmet.2020.101115. Epub 2020 Nov 10. Mol Metab. 2021. PMID: 33186758 Free PMC article. Review.
-
Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease.Curr Drug Targets. 2015;16(12):1301-14. doi: 10.2174/1389450116666150427155342. Curr Drug Targets. 2015. PMID: 25915484 Review.
-
Non-Alcoholic Fatty Liver Disease.Adv Exp Med Biol. 2017;960:443-467. doi: 10.1007/978-3-319-48382-5_19. Adv Exp Med Biol. 2017. PMID: 28585211 Review.
-
Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH.FASEB J. 2015 Apr;29(4):1564-76. doi: 10.1096/fj.14-264937. Epub 2015 Jan 21. FASEB J. 2015. PMID: 25609431
-
Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.Clin Liver Dis. 2018 Feb;22(1):23-37. doi: 10.1016/j.cld.2017.08.007. Epub 2017 Oct 18. Clin Liver Dis. 2018. PMID: 29128059 Review.
Cited by
-
Ferroptosis: Shedding Light on Mechanisms and Therapeutic Opportunities in Liver Diseases.Cells. 2022 Oct 20;11(20):3301. doi: 10.3390/cells11203301. Cells. 2022. PMID: 36291167 Free PMC article. Review.
-
Hu-lu-su-pian ameliorates hepatic steatosis by regulating CIDEA expression in AKT-driven MASLD mice.Front Pharmacol. 2025 Jan 31;15:1503247. doi: 10.3389/fphar.2024.1503247. eCollection 2024. Front Pharmacol. 2025. PMID: 39958875 Free PMC article.
-
Nrf2 activation: a key mechanism in stem cell exosomes-mediated therapies.Cell Mol Biol Lett. 2024 Mar 2;29(1):30. doi: 10.1186/s11658-024-00551-3. Cell Mol Biol Lett. 2024. PMID: 38431569 Free PMC article. Review.
-
Bornyl-Containing Derivatives of Benzyloxyphenylpropanoic Acid as FFAR1 Agonists: In Vitro and In Vivo Studies.Pharmaceutics. 2023 Jun 7;15(6):1670. doi: 10.3390/pharmaceutics15061670. Pharmaceutics. 2023. PMID: 37376118 Free PMC article.
-
Short-chain fatty acids in nonalcoholic fatty liver disease: New prospects for short-chain fatty acids as therapeutic targets.Heliyon. 2024 Feb 27;10(5):e26991. doi: 10.1016/j.heliyon.2024.e26991. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38486722 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous